Second Sight Medical Products Inc.
| NASDAQ: EYES |
| Healthcare / Medical Devices & Instruments / USA |
| 2.33 | +0.0600 | +2.64% | Vol 135.22K | 1Y Perf -56.84% |
| Jun 24th, 2022 16:00 DELAYED |
| BID | 2.28 | ASK | 2.35 | ||
| Open | 2.31 | Previous Close | 2.27 | ||
| Pre-Market | - | After-Market | 2.34 | ||
| - - | 0.01 0.43% |
| Target Price | 12.00 | Analyst Rating | — 0.00 | |
| Potential % | 415.02 | Finscreener Ranking | ★★+ — - | |
| Insiders Trans % 3/6/12 mo. | 100/100/100 | Value Ranking | ★★★★★ 61.92 | |
| Insiders Value % 3/6/12 mo. | 100/100/100 | Growth Ranking | ★★★+ 56.38 | |
| Insiders Shares Cnt. % 3/6/12 mo. | 100/100/100 | Income Ranking | — - | |
| Price Range Ratio 52W % | 27.93 | Earnings Rating | Neutral | |
| Market Cap | 91.82M | Earnings Date | 27th Jun 2022 | |
| Alpha | 0.02 | Standard Deviation | 0.54 | |
| Beta | 2.81 |
Today's Price Range 2.252.35 | 52W Range 1.145.40 | 5 Year PE Ratio Range -1.70-0.3000 |
Summary:
Buy
| Technical Indicators: | Buy |
| Moving Averages: | Strong Buy |
| Performance | |||
|---|---|---|---|
| 1 Week | 9.91% | ||
| 1 Month | 30.90% | ||
| 3 Months | 58.50% | ||
| 6 Months | 20.73% | ||
| 1 Year | -56.84% | ||
| 3 Years | -63.93% | ||
| 5 Years | -75.53% | ||
| 10 Years | - |
| Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
ROE (5Y Avg) | -98.86 | |||
ROE last 12 Months | -19.28 | |||
ROA (5Y Avg) | -23.27 | |||
ROA last 12 Months | -17.43 | |||
ROC (5Y Avg) | -253.19 | |||
ROC last 12 Months | -18.47 | |||
Return on invested Capital Q | -3.28 | |||
Return on invested Capital Y | -1.85 | |||
Assets Turnover | 0.00 | |||
Receivables Turnover | 0.00 |
| Valuation | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| -10.10 | ||||
| 1.32 | ||||
| 101.87 | ||||
| - | ||||
| -8.40 | ||||
| -0.28 | ||||
| 1.32 | ||||
| 1.68 | ||||
| 28.09M | ||||
| Forward PE | -1.47 | |||
| PEG | - |
| Financial Strength | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 25.00 | ||||
| 25.20 | ||||
| 0.00 | ||||
| 0.00 | ||||
| - | ||||
| Leverage Ratio | 1.00 |
| Profitability | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 75.10 | ||||
| -3 915.30 | ||||
| -3 864.60 | ||||
| -973.20 | ||||
| - |
| Revenue | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 0.00 | ||||
| 0.00 | ||||
| -50.53 | ||||
| -30.37 |
| Dividends | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| Payout ratio | - |
| Earnings History | Estimate | Reported | Surprise % |
|---|---|---|---|
| Q02 2020 | - | -0.15 | - |
| Q04 2019 | -0.49 | -0.47 | 4.08 |
| Q03 2019 | -0.48 | -0.48 | 0.00 |
| Q02 2019 | -0.48 | -0.56 | -16.67 |
| Q01 2019 | -0.48 | -0.80 | -66.67 |
| Q04 2018 | -0.88 | -0.88 | 0.00 |
| Q03 2018 | -1.12 | -0.96 | 14.29 |
| Q02 2018 | -0.14 | -0.12 | 14.29 |
| Earnings Per End | Estimate | Revision % | Trend |
|---|---|---|---|
| 9/2020 QR | -0.41 | 0.00 | - |
| 12/2020 QR | -0.42 | 0.00 | - |
| 12/2020 FY | -1.64 | 0.00 | - |
| 12/2021 FY | -1.39 | 0.00 | - |
| Next Report Date | 27th Jun 2022 |
| Estimated EPS Next Report | - |
| Estimates Count | - |
| EPS Growth Next 5 Years % | - |
| Volume Overview | |
|---|---|
| Volume | 135.22K |
| Shares Outstanding | 39.41K |
| Shares Float | 29.48M |
| Trades Count | 1.00K |
| Dollar Volume | 312.67K |
| Avg. Volume | 292.81K |
| Avg. Weekly Volume | 200.39K |
| Avg. Monthly Volume | 331.96K |
| Avg. Quarterly Volume | 346.06K |
Second Sight Medical Products Inc. (NASDAQ: EYES) stock closed at 2.33 per share at the end of the most recent trading day (a 2.64% change compared to the prior day closing price) with a volume of 135.22K shares and market capitalization of 91.82M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Medical Devices & Instruments industry, Healthcare sector and employs 112 people. Second Sight Medical Products Inc. CEO is Matthew J. Pfeffer.
The one-year performance of Second Sight Medical Products Inc. stock is -56.84%, while year-to-date (YTD) performance is 42.94%. EYES stock has a five-year performance of -75.53%. Its 52-week range is between 1.14 and 5.3999, which gives EYES stock a 52-week price range ratio of 27.93%
Second Sight Medical Products Inc. currently has a PE ratio of -10.10, a price-to-book (PB) ratio of 1.32, a price-to-sale (PS) ratio of 101.87, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -17.43%, a ROC of -18.47% and a ROE of -19.28%. The company’s profit margin is -%, its EBITDA margin is -3 864.60%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.
Of the last four earnings reports from Second Sight Medical Products Inc., there were 1 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $0.00 for the next earnings report. Second Sight Medical Products Inc.’s next earnings report date is 27th Jun 2022.
The consensus rating of Wall Street analysts for Second Sight Medical Products Inc. is — (0), with a target price of $12, which is +415.02% compared to the current price. The earnings rating for Second Sight Medical Products Inc. stock is Neutral (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Second Sight Medical Products Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Second Sight Medical Products Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 42.76, ATR14 : 0.16, CCI20 : 28.17, Chaikin Money Flow : 0.10, MACD : 0.10, Money Flow Index : 58.17, ROC : -3.32, RSI : 59.98, STOCH (14,3) : 47.14, STOCH RSI : 1.00, UO : 46.80, Williams %R : -52.86), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Second Sight Medical Products Inc. in the last 12-months were: Gregg Williams (Buy at a value of $455 946)
Second Sight Medical Products Inc.
Second Sight Medical Products Inc develops, manufactures and markets implantable prosthetic devices, to create an artificial form of useful vision for blind individuals. The company's product Argus II System treats outer retinal degenerations, such as Retinitis Pigmentosa, often referred to as RP. The company generates revenue from the sale of its Argus II retinal prosthesis systems, which include the implant and external components. Geographically, the company operates in the United States, Italy, France and Germany, of which key revenue is derived from the United States.
CEO: Matthew J. Pfeffer
Telephone: +1 818 833-5000
Address: 12744 San Fernando Road, Sylmar 91342, CA, US
Number of employees: 112
